SCHEMBL3760601

SCHEMBL3760601

CCOC(=O)c1c(N)sc2c1CC(C)(C)CNC2=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K2 P36507 2/20 0.56
MAP2K1 Q02750 2/20 0.56
ALDH1A1 P00352 11/20 0.50
MAPT P10636 9/20 0.50
HPGD P15428 9/20 0.50
GAA P10253 7/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 4/20 0.49
HSD17B10 Q99714 4/20 0.49
ALOX15 P16050 3/20 0.49
MAPK1 P28482 3/20 0.49
ADORA1 P30542 2/20 0.48
TSHR P16473 1/20 0.47
ALOX12 P18054 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
POLB P06746 1/20 0.47
RECQL P46063 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3754839 0.86 MAP2K2 (0.57) MAP2K2MAP2K1ALDH1A1MAPTMAPK1
SCHEMBL3760020 0.86 ALDH1A1 (0.51) MAP2K2MAP2K1ALDH1A1MAPTHPGD
SCHEMBL3764678 0.80 MAP2K2 (0.49) MAP2K2MAP2K1ALDH1A1HPGDGAA
SCHEMBL3740600 0.73 KMT2A (0.57) ALDH1A1MAPTHPGDGAASMN1; SMN2
SCHEMBL12470114 0.73 ALDH1A1 (0.67) ALDH1A1MAPTHPGDGAASMN1; SMN2
SCHEMBL21247315 0.73 ALDH1A1 (0.54) ALDH1A1MAPTHPGDGAASMN1; SMN2
SCHEMBL4019351 0.73 MAP2K2 (1.00) MAP2K2MAP2K1
SCHEMBL4503267 0.73 MAP2K2 (1.00) MAP2K2MAP2K1ALDH1A1MAPK1TDP1
SCHEMBL3761551 0.72 MAP2K2 (0.44) MAP2K2MAP2K1ALDH1A1MAPTHPGD
SCHEMBL12470113 0.72 MAPT (0.65) ALDH1A1MAPTHPGDGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
US-20090264411-A1 FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS UCB PHARMA S.A. (BE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264411-A1 FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS MAPK15, MOK, MAPK14 MAP2K2 9/4885MAP2K1 12/4885ALDH1A1 3718/4885
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA MAP2K2 44/4885MAP2K1 87/4885ALDH1A1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.